AI-Driven Amino Acid Drugs Surface as a Promising Treatment for Eye Conditions

The rapid evolution of artificial intelligence (AI) promises to revolutionize multiple sectors, and one area seeing tangible benefits is drug development. Historically, the creation of new medicines was a time-consuming endeavor, but AI-driven amino acid research is proving to accelerate the early developmental stages and get drugs to the market faster.

Researchers at the Wilmer Eye Institute and Johns Hopkins Medicine have now harnessed artificial intelligence (AI) to predict which amino acid components in therapeutic proteins can effectively deliver drugs to animal eye cells. By deeply understanding protein structures, AI can refine drug formulations, potentially minimizing harmful side effects while helping to treat eye conditions such as glaucoma and macular degeneration.

But how reliable are these AI-driven amino acid models for drug delivery, and where do they stack up when it comes to current drug delivery methods such as eye drops or implantable devices? To explore AI’s potential in this field, we turn to an expert Dr. Christopher Clark, Professor at Indiana University.

Christopher’s Thoughts:

“Hi. I’m Dr. Christopher Clark, a professor at Indiana University.

AI offers an amazing tool for the development of new drugs. The biggest gain is speed to market. What that means is the early stage of development where we can reduce the amount of time that a drug takes to get to market. All that though is is in the developmental time, not in the testing time.

Now, Any AI developed drug probably can have some side effects as well, potentially serious. For that reason why, they’re going to have to go through the same FDA testing that any other drug is developed, and that’s going to take the exact same amount of time. So really the game for AI is in the development at this moment in time, not in the testing itself, which still is substantially months to years in often, in most cases. That is to say in no way does AI develop treatments, are any less safe than traditional treatments.

Oftentimes, the AI development may remove some of the serious side effects from drugs that are coming out of the market because they look at that protein structure, and they remove the protein structure that causes some of those side effects or can reduce or remove those proteins to make those side effects less. AI developed amino acid sequencing models like DeepMine’s AlphaFold have been shown to be very accurate and identify protein structures of millions of proteins.

With this understanding of the protein structure, it’s highly possible to improve drug delivery to the structures of these such as the eye. An example of that is think of eye drops. We put a drop on top of the cornea. That drop has to penetrate through multiple layers of that cornea to get into the eye to treat the things inside the eye like macular degeneration, cataracts, things like inflammatory mediators inside the eye.

Because those different layers are both hydrophobic and hydrophilic going back forth, it is really tough to get our drugs currently from the front of the eye back to that eye because penetration isn’t very good. What does hydrophobic and hydrophilic mean? Think of it like trying to send some something through multiple layers of oil, water, oil, water. It’s really tough to get a molecule to go and do that.

AI offers a potential there to get better penetration to inside the eye itself by circumventing some of these features of the eye, and thereby improving the overall quality of treatment that we have for our eyes.”

Article written by Cara Schildmeyer.

Follow us on social media for the latest updates in B2B!

Image

Latest

zero trust architecture
Secure Grid Modernization with Zero Trust Architecture
April 19, 2024

Ray Bauer of Verizon Business engages with Del Rodriguez from Palo Alto Networks at DISTRIBUTECH 2024. Rodriguez shares insights into the significance of cybersecurity within the utility sector, particularly in light of increasing cyber threats and the convergence of IT and operational technology (OT). Bauer and Rodriguez discuss Palo Alto Networks’ initiatives to enhance […]

Read More
private wireless networks
Private Wireless Networks
April 19, 2024

Verizon host Wayne Weeks discusses the evolving utility industry with John Gaster, CEO of KSI Data Sciences at DISTRIBUTECH 2024. Together, they explore how KSI focuses on harnessing data from remote sensing devices to enhance the safety, efficiency, and cost-effectiveness of utility operations. Gaster emphasizes the significant role of AI and machine learning in […]

Read More
5G network platforms
5G Network Platforms
April 19, 2024

Verizon host Matt Montgomery chats with Blaze Vincent and Thedy Wana from Ericsson, where they discuss pressing challenges and opportunities within the utility sector, emphasizing the significant role of digital transformation and 5G technology in addressing these issues. The conversation highlights Ericsson’s contributions to smart grid modernization and how their innovative solutions are tailored […]

Read More
5G security policies
Leveraging 5G to Extend Security Policies
April 19, 2024

Guests Jeff Brown and Carlos Augusto from Fortinet join Brett Barganz of Verizon to discuss the integration of extended security policies with 5G technology at DISTRIBUTECH 2024. They delve into the transformation and challenges in cybersecurity within the utility sector, highlighting the strategic partnership between Fortinet and Verizon to advance security solutions that leverage […]

Read More